An isolated antibody, comprising a light-chain CDR1 (L-CDR1) having the sequence of SEQ ID NO: 1, SEQ ID NO: 7, or SEQ ID NO: 14； a light-chain CDR2 (L-CDR2) having the sequence of SEQ ID NO: 2 or SEQ ID NO: 15； a light-chain CDR3 (L-CDR3) having the sequence of SEQ ID NO: 3, SEQ ID NO: 8, SEQ ID NO: 21, or SEQ ID NO: 24； a heavy-chain CDR1 (H-CDR1) having the sequence of SEQ ID NO: 4, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 16, or SEQ ID NO: 25； a heavy-chain CDR2 (H-CDR2) having the sequence of SEQ ID NO: 5, SEQ ID NO: 12, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 22, or SEQ ID NO: 26； and a heavy-chain CDR3 (H-CDR3) having the sequence of SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 23, or SEQ ID NO: 27, wherein the antibody specifically binds to Aβ1-42or an N-terminal modified form thereof.一種分離的抗體，其結構包含：一輕鏈CDR1 (L-CDR1)，具有SEQ ID NO: 1序列、SEQ ID NO: 7序列、或 SEQ ID NO: 14序列；一輕鏈CDR2 (L-CDR2)，具有SEQ ID NO: 2序列或 SEQ ID NO: 15序列；一輕鏈CDR3 (L-CDR3)，具有SEQ ID NO: 3序列、SEQ ID NO: 8序列、SEQ ID NO: 21序列、或SEQ ID NO: 24序列；一重鏈CDR1 (H-CDR1)，具有SEQ ID NO: 4序列、SEQ ID NO: 9序列、SEQ ID NO: 11序列、SEQ ID NO: 16序列、或SEQ ID NO: 25序列；一重鏈CDR2 (H-CDR2)，具有SEQ ID NO: 5序列、SEQ ID NO: 12序列、SEQ ID NO: 17序列、SEQ ID NO: 19序列、SEQ ID NO: 22序列、或SEQ ID NO: 26序列；以及一重鏈CDR3 (H-CDR3) ，具有SEQ ID NO: 6序列、SEQ ID NO: 10序列、SEQ ID NO: 13序列、SEQ ID NO: 18序列、SEQ ID NO: 20序列、SEQ ID NO: 23序列、或SEQ ID NO: 27序列；其中該抗體對Aβ1-42或一N端修飾型Aβ1-42皆具有特異性結合能力。
